Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06961214 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Study acronym: ENDURA-2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry Show 7 more changesShow less
    • Trial sites expanded: 159 → 193 locations
    • Primary completion moved earlier from Aug 21, 2029 to Dec 13, 2028
    • Study completion moved earlier from Aug 21, 2029 to Feb 14, 2029
    • Interventions modified
    • Enrollment target: 960 to 961
    • Eligibility criteria shortened, about 8 words
    • Secondary endpoints: details revised at 4 of 5 entries
  2. Study sites: 1 to 159v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Aug 6, 2029 to Aug 21, 2029
    • Start date changed from estimate of Jun 6, 2025 to Jun 23, 2025
    • Study description shortened, about 5 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
COPD
1,119 trials monitored
See 34 trials at risk
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Trial Details
NCT Number NCT06961214
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Pulmonary Disease, Chronic Obstructive
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 961 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov